Bionic Sight Reports Meaningful Vision Improvements for RP Patients Receiving...
All 12 patients dosed thus far in a Phase ½ dose-escalation clinical trial for Bionic Sight’s emerging optogenetic treatment have demonstrated significant vision improvements. Those receiving the...
View ArticleBudd Tucker Honored with ARVO’s Cogan Award for Advancements in Retinal...
Budd Tucker, PhD, a highly innovative retinal-disease therapy developer and manufacturing expert from the University of Iowa, received the prestigious Cogan Award on April 26 at the 2023 annual...
View ArticleEric Pierce Receives Proctor Medal for Outstanding Achievements in Retinal...
Eric Pierce, MD, PhD, a world-renowned clinician-scientist dedicated to eradicating inherited retinal diseases (IRDs), was honored with the prestigious Proctor Medal on April 24 at the 2023 annual...
View ArticleAtsena Receives FDA Authorization to Launch a Gene Therapy Clinical Trial for...
Atsena Therapeutics, a company developing gene therapies for inherited retinal diseases (IRDs), has received authorization from the US Food and Drug Administration (FDA) to launch a Phase ½ clinical...
View ArticleSummary of the Eighth Annual Retinal Cell & Gene Therapy Innovation Summit 2023
The Retinal Cell and Gene Therapy Innovation Summit has emerged as one of the most essential events for researchers and companies developing treatments and cures for retinal degenerative diseases. In...
View ArticleCoave Reports Encouraging Phase 1/2 Clinical Trial Results for PDE6B Gene...
Coave Therapeutics, a French biotechnology company, announced that its gene therapy for people with retinitis pigmentosa (RP) caused by mutations in the gene PDE6B improved visual function at 12...
View ArticleBeacon Therapeutics to Advance XLRP, Cone-Rod Dystrophy, and Dry AMD Gene...
Beacon Therapeutics, a company focused on development of gene therapies for retinal diseases, has been launched with £96 million ($120 million) in investments from Syncona Limited, Oxford Sciences...
View ArticleUniversity of Wisconsin-Madison Awarded $29 Million NIH Common Fund Grant to...
The five-year grant will advance the emerging treatments toward clinical trials A multi-disciplinary retinal research team from the University of Wisconsin-Madison (UWM) has been awarded a five-year,...
View ArticlePYC Doses First Patient in Clinical Trial of RNA Therapy for RP11 (PRPF31...
PYC Therapeutics, an Australia-based developer of RNA therapies, has launched a Phase 1 clinical trial for its RNA therapy known as VP-001 for people with retinitis pigmentosa 11 (RP11) which is...
View ArticleBelite Bio Doses First Patient in Phase 3 Clinical Trial for Advanced Dry AMD...
Belite Bio, a biopharmaceutical company developing therapies for retinal degenerative diseases, has dosed the first patient in its Phase 3 PHOENIX clinical trial of Tinlarebant for the treatment of...
View ArticleIZERVAY Approved by FDA for Treatment of Geographic Atrophy Secondary to...
Astellas Pharma Inc. has announced that the U.S. Food and Drug Administration (FDA) approved IZERVAY™ (avacincaptad pegol) for the treatment of geographic atrophy (GA) secondary to advanced dry...
View ArticleFDA Approves 8 MG Dosing of Eylea for Wet AMD, Diabetic Macular Edema, and...
Regeneron, a global developer of biologic therapies, has announced that the US Food and Drug Administration (FDA) has approved 8 mg ocular injections of Eylea® (aflibercept) for the treatment of wet...
View ArticleAtsena Doses First Patient in XLRS Gene Therapy Clinical Trial
Atsena Therapeutics, a company developing gene therapies for inherited retinal diseases (IRDs), has dosed the first person in a Phase ½ clinical trial for its X-linked retinoschisis (XLRS) gene...
View ArticleSparingVision Recruiting for Clinical Trial of Cone-Preserving Gene Therapy...
SparingVision, a French company developing therapies for ocular conditions including inherited retinal diseases, has dosed the first cohort of patients at the low dose in its Phase ½ clinical trial...
View ArticleFoundation Funds 25 New Grants Totaling $15.1 Million in FY23
The Foundation Fighting Blindness added 25 new research projects to its portfolio, an investment totaling $15.1 million, during its Fiscal Year 2023 (ending June 30, 2023). Project awards ranged from...
View ArticleFirst Patient Dosed in LCA5 Gene Therapy Clinical Trial Launched by Opus...
Opus Genetics, a company developing gene therapies for people with inherited retinal diseases, has dosed the first patient in its Phase ½ gene therapy clinical for Leber congenital amaurosis 5 (LCA5),...
View ArticleOcugen Reports Updated Results for Clinical Trial of Modifier Gene Therapy
The biotech company Ocugen provided an update on the Phase ½ clinical trial for OCU400, its emerging, modifier gene therapy, which delivers copies of the NR2E3 gene to improve regulation of multiple...
View ArticleNew Report: Vitamin A Supplementation Provides No Vision Benefit to RP Patients
A Mass Eye and Ear research team led by Eric Pierce, MD, PhD, director of the Ocular Genomics Institute, and Jason Comander, MD, PhD, director of the Inherited Retinal Disorders Service, has...
View ArticleKiora Reports Vision Restoration in Phase 1/2 Clinical Trial for Photoswitch...
Kiora Pharmaceuticals has announced some vision restoration for participants in ABACUS-1, its Phase ½ clinical trial in Australia for KIO-301, a molecule designed to bestow light sensitivity to retinal...
View ArticleThéa Completes Acquisition of ProQR’s LCA10 and USH2A Treatment Programs,...
Laboratoires Théa, the leading European developer of eye care products, has acquired two emerging antisense oligonucleotide (AON) treatments for inherited retinal diseases from ProQR Therapeutics....
View Article
